These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 18651855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
    Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, Edwards S, Pillay D.
    AIDS; 2009 Oct 23; 23(16):2159-64. PubMed ID: 19571721
    [Abstract] [Full Text] [Related]

  • 5. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
    Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05).
    Antivir Ther; 2011 Oct 23; 16(6):937-40. PubMed ID: 21900727
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R.
    J Med Virol; 2010 Jan 23; 82(1):116-22. PubMed ID: 19950236
    [Abstract] [Full Text] [Related]

  • 8. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
    AIDS Rev; 2009 Jan 23; 11(1):17-29. PubMed ID: 19290031
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evolution of raltegravir resistance during therapy.
    Sichtig N, Sierra S, Kaiser R, Däumer M, Reuter S, Schülter E, Altmann A, Fätkenheuer G, Dittmer U, Pfister H, Esser S.
    J Antimicrob Chemother; 2009 Jul 23; 64(1):25-32. PubMed ID: 19447792
    [Abstract] [Full Text] [Related]

  • 11. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY, BENCHMRK Study Teams.
    N Engl J Med; 2008 Jul 24; 359(4):355-65. PubMed ID: 18650513
    [Abstract] [Full Text] [Related]

  • 12. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.
    J Med Virol; 2012 Dec 24; 84(12):1869-75. PubMed ID: 23080489
    [Abstract] [Full Text] [Related]

  • 13. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R.
    Virology; 2010 Jul 05; 402(2):338-46. PubMed ID: 20421122
    [Abstract] [Full Text] [Related]

  • 14. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, ANRS HIV-2 Co5 Cohort.
    AIDS; 2008 Oct 01; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.
    Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, Si-Mohamed A, Weiss L.
    AIDS; 2010 Mar 27; 24(6):867-73. PubMed ID: 20160635
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M, Toro C, Simón A, Garrido C, Blanco F, Soriano V, Rodés B.
    J Clin Virol; 2009 Oct 27; 46(2):173-5. PubMed ID: 19625211
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.